Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
00RYdymn5ym0mqRq